Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness
CADTH
Record ID 32012000695
English
Authors' recommendations:
Infliximab was found to be more effective than methotrexate, etanercept, adalimumab, and ustekinumab through meta-analyses and one randomized controlled trial. Limited data on safety found that the use of infliximab was associated with an increased risk of experiencing an adverse event than methotrexate or 50 mg etanercept. Despite having a high efficacy, the recommended dose of 5mg/kg infliximab was found to be less cost effective than methotrexate, 25 mg etanercept, adalimumab, or 90 mg ustekinumab.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/media/pdf//htis/aug-2012/RC0369%20Infliximab%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antibodies, Monoclonal
- Dermatologic Agents
- Methotrexate
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Antibodies, Monoclonal, Humanized
- Cost-Benefit Analysis
- Infliximab
- Etanercept
- Adalimumab
- Ustekinumab
- Psoriasis
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.